Ursodeoxycholic acid and severe COVID-19 outcomes in people with liver disease: a cohort study using the OpenSAFELY platform
Abstract Biological evidence suggests ursodeoxycholic acid (UDCA) - a common treatment of cholestatic liver disease - may prevent severe COVID-19 outcomes. With the approval of NHS England, we conducted a population-based cohort study using primary care records, linked to death registration data and hospital records through the OpenSAFELY-TPP platform. We estimated the hazard of COVID-19 hospitalisation or death between 1 March 2020 and 31 December 2022, comparing UDCA treatment to no UDCA treatment in a population with indication. Of 11,320 eligible individuals, 642 were hospitalised or died with COVID-19 during follow-up, 402 (63%) events among UDCA users. After confounder adjustment, UDCA was associated with a 21% (95% CI 7%-33%) relative reduction in the hazard of COVID-19 hospitalisation or death, consistent with an absolute risk reduction of 1.3% (95% CI 1.0%-1.6%). Our findings support calls for clinical trials investigating UDCA as a preventative measure for severe COVID-19 outcomes..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 15. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Costello, Ruth E [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.12.11.23299191 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI041866118 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI041866118 | ||
| 003 | DE-627 | ||
| 005 | 20231216132546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231214s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.12.11.23299191 |2 doi | |
| 035 | |a (DE-627)XBI041866118 | ||
| 035 | |a (biorXiv)10.1101/2023.12.11.23299191 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Costello, Ruth E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ursodeoxycholic acid and severe COVID-19 outcomes in people with liver disease: a cohort study using the OpenSAFELY platform |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Biological evidence suggests ursodeoxycholic acid (UDCA) - a common treatment of cholestatic liver disease - may prevent severe COVID-19 outcomes. With the approval of NHS England, we conducted a population-based cohort study using primary care records, linked to death registration data and hospital records through the OpenSAFELY-TPP platform. We estimated the hazard of COVID-19 hospitalisation or death between 1 March 2020 and 31 December 2022, comparing UDCA treatment to no UDCA treatment in a population with indication. Of 11,320 eligible individuals, 642 were hospitalised or died with COVID-19 during follow-up, 402 (63%) events among UDCA users. After confounder adjustment, UDCA was associated with a 21% (95% CI 7%-33%) relative reduction in the hazard of COVID-19 hospitalisation or death, consistent with an absolute risk reduction of 1.3% (95% CI 1.0%-1.6%). Our findings support calls for clinical trials investigating UDCA as a preventative measure for severe COVID-19 outcomes. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Jean Waller, Karen Maree |4 aut | |
| 700 | 1 | |a Smith, Rachel |4 aut | |
| 700 | 1 | |a Mells, George F |4 aut | |
| 700 | 1 | |a Wong, Angel YS |4 aut | |
| 700 | 1 | |a Schultze, Anna |4 aut | |
| 700 | 1 | |a Mahalingasivam, Viyaasan |4 aut | |
| 700 | 1 | |a Herrett, Emily |4 aut | |
| 700 | 1 | |a Zheng, Bang |4 aut | |
| 700 | 1 | |a Lin, Liang-Yu |4 aut | |
| 700 | 1 | |a Mehrkar, Amir |4 aut | |
| 700 | 1 | |a Bacon, Sebastian CJ |4 aut | |
| 700 | 1 | |a Goldacre, Ben |0 (orcid)0000-0002-5127-4728 |4 aut | |
| 700 | 1 | |a Tomlinson, Laurie A |4 aut | |
| 700 | 1 | |a Tazare, John |4 aut | |
| 700 | 1 | |a Rentsch, Christopher T |0 (orcid)0000-0002-1408-7907 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 15. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.12.11.23299191 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 15 |c 12 | ||